Insiders of POINT Biopharma Global Sell Over US$4.2m in Stock to Hedge Losses Despite Market Cap Decline in 2023.
March 22, 2023
Trending News 🌧️
The significant decline in POINT ($NASDAQ:PNT) Biopharma Global Inc.’s market cap in 2023 to US$766m, has caused considerable concern for the company’s shareholders. This move by the company’s insiders is seen as a response to the decline in market cap, and has left many wondering if it is enough to offset the losses incurred from the drastic drop in share price. The sale of US$4.2m worth of stock is a substantial amount for any company, and it is clear that POINT Biopharma Global Inc. insiders have taken a calculated risk in order to minimize the extent of their losses.
While this move may not fully prevent the decline in market cap, it is certainly a prudent move given the current state of the company’s finances and stock value. In the meantime, it is clear that the company’s insiders have taken action to protect their own investments and hedge any potential losses.
Share Price
On the same day, POINT BIOPHARMA GLOBAL’s stock opened at $7.9 and closed at $7.9, up by 0.9% from the prior closing price of 7.8. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for PNT. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -79.17 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for PNT. More…
| Operations | Investing | Financing |
| -64.92 | -179.02 | 116.9 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for PNT. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 325.69 | 16.61 | 2.97 |
Key Ratios Snapshot
Some of the financial key ratios for PNT are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | – |
| FCF Margin | ROE | ROA |
| – | -19.1% | -15.4% |
Analysis
At GoodWhale, we’ve taken a deep dive into POINT BIOPHARMA GLOBAL’s financials and determined that it is a high risk investment. We use our Risk Rating system to evaluate the financial and business aspects of a company, and we’ve determined that POINT BIOPHARMA GLOBAL falls into our high risk category. We’ve also detected 3 risk warnings that our users can learn more about by registering with us. These risk warnings involve the balance sheet, cashflow statement, and non-financial aspects of the company. This means that anyone who invests in POINT BIOPHARMA GLOBAL should do so with caution and due diligence. At GoodWhale, we are committed to providing our users with the most up-to-date information and analysis on any given company. With that in mind, we highly recommend our users to register with us so they can access all of our detailed risk warnings and assessments. That way, they can make an informed decision about their investments in POINT BIOPHARMA GLOBAL. More…
Peers
The company’s main competitors are Annovis Bio Inc, Plus Therapeutics Inc, and Jazz Pharmaceuticals PLC. All of these companies are working to develop new and innovative treatments for cancer.
– Annovis Bio Inc ($NYSE:ANVS)
Annovis Bio Inc is a clinical stage biopharmaceutical company developing a pipeline of therapeutic candidates for the treatment of neurological diseases. The company’s lead product candidate, ANVS-401, is a monoclonal antibody being developed for the treatment of Alzheimer’s disease. Annovis Bio Inc has a market cap of 100.01M as of 2022, a Return on Equity of -37.92%.
Annovis Bio Inc is a clinical stage biopharmaceutical company developing a pipeline of therapeutic candidates for the treatment of neurological diseases. The company’s lead product candidate, ANVS-401, is a monoclonal antibody being developed for the treatment of Alzheimer’s disease. Annovis Bio Inc’s market cap is 100.01M as of 2022, and its ROE is -37.92%.
– Plus Therapeutics Inc ($NASDAQ:PSTV)
The company’s market cap is 14.14M as of 2022 and its ROE is -106.7%. The company is engaged in the development of therapeutics for the treatment of cancer.
– Jazz Pharmaceuticals PLC ($NASDAQ:JAZZ)
Jazz Pharmaceuticals PLC is a biopharmaceutical company that focuses on the research, development, and commercialization of pharmaceutical products. The company has a market cap of $9.11 billion and a return on equity of 4.24%. Jazz Pharmaceuticals PLC focuses on the treatment of central nervous system disorders, including sleep disorders, pain, and psychiatric disorders. The company’s products include Xyrem, Erwinaze, Defitelio, and Vyxeos.
Summary
POINT Biopharma Global Inc. has experienced a downturn in its market capitalization in 2023, leading insiders to sell over US$4.2 million worth of stock to protect against potential losses. Despite this, analysts still view the company’s prospects as positive, citing its diverse product portfolio, ongoing clinical trials, and potential partnerships. Investors should also note POINT Biopharma Global Inc.’s strong balance sheet, with healthy cash reserves and an ongoing cost-control strategy.
Moreover, the company’s innovative use of technology and data has enabled it to bring new treatments to market faster than competitors. Overall, POINT Biopharma Global Inc. is still a viable investment opportunity for those willing to accept the risk associated with the inherent volatility of biopharmaceutical stocks.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
